# A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

> **NCT02653976** · PHASE2 · COMPLETED · sponsor: **Solasia Pharma K.K.** · enrollment: 67 (actual)

## Conditions studied

- Peripheral T-Cell Lymphoma

## Interventions

- **DRUG:** SP-02L (darinaparsin for injection)

## Key facts

- **NCT ID:** NCT02653976
- **Lead sponsor:** Solasia Pharma K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-25
- **Primary completion:** 2020-10-11
- **Final completion:** 2021-06-17
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2024-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02653976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02653976, "A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02653976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*